Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelm

The F.D.A. also required Biogen to conduct another clinical trial to determine if the drug provided any evidence of benefit. In the years it will take for that trial to be completed, Aduhelm will be available to patients. Medicare’s coverage decision is considered pivotal to the future of Aduhelm, which is priced at $28,200 a […]

Saubio's Promo Tools
Continue Reading


Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision

Posts supporting coverage include comments from people who have consulted for Biogen, like Dr. Jeffrey Cummings, a research professor in the department of brain health at the University of Nevada Las Vegas. He wrote that the drug “prolongs the mental life of our declining patients,” adding, “Medicare should unequivocally support coverage for aducanumab, and they […]

Saubio's Promo Tools
Continue Reading


Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstacles

Biogen slashed the price of its controversial new Alzheimer’s drug Aduhelm on Monday as the drug faces weak sales and mounting criticism. The price was reduced to $28,200 a year from $56,000 on the same day that a group of Alzheimer’s experts and health advocates called on the Food and Drug Administration to pull the […]

Saubio's Promo Tools
Continue Reading


Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug

Safety data from those trials was published Monday in the journal JAMA Neurology in a study whose authors included eight Biogen employees. The data showed that 425 of 1,029 patients, or 41 percent, who received the high dose of the drug — the dose that the F.D.A. later approved — experienced either brain swelling or […]

Saubio's Promo Tools
Continue Reading